119646-48-9

Basic information

• Product Name: 4-(HYDROXYMETHYL)PYRIDINE-2-CARBOXAMIDE
• Synonyms: 4-(HYDROXYMETHYL)PYRIDINE-2-CARBOXAMIDE;2-Pyridinecarboxamide,4-(hydroxymethyl)-(9CI)
• CAS NO: 119646-48-9
• Molecular Formula: C7H8N2O2
• Molecular Weight: 152.15
• Product Categories: AMIDE
• Mol File: 119646-48-9.mol

Chemical Properties

• Boiling Point: 388.4±32.0 °C(Predicted)
• Appearance: /
• Density: 1.321±0.06 g/cm3(Predicted)
• PKA: 13.25±0.10(Predicted)
• CAS DataBase Reference: 4-(HYDROXYMETHYL)PYRIDINE-2-CARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(HYDROXYMETHYL)PYRIDINE-2-CARBOXAMIDE(119646-48-9)
• EPA Substance Registry System: 4-(HYDROXYMETHYL)PYRIDINE-2-CARBOXAMIDE(119646-48-9)

Safety Data

• Hazardous Substances Data: 119646-48-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(Hydroxymethyl)pyridine-2-carboxamide is used as a building block in the synthesis of pharmaceuticals and fine chemicals. Its versatile reactivity allows for the creation of a wide range of compounds with potential therapeutic applications.
Used in Coordination Complexes:
In the field of coordination chemistry, 4-(Hydroxymethyl)pyridine-2-carboxamide is used as a ligand to form coordination complexes. These complexes can exhibit unique properties and have potential applications in various areas, such as catalysis, sensing, and materials science.
Used in Chelating Agent Development:
4-(Hydroxymethyl)pyridine-2-carboxamide has shown potential as a chelating agent, which can be used to bind and remove metal ions from various systems. This property can be applied in environmental remediation, water treatment, and other industrial processes.
Used in Antimicrobial and Antiparasitic Applications:
4-(Hydroxymethyl)pyridine-2-carboxamide has been studied for its antimicrobial and antiparasitic properties, making it a candidate for the development of new drugs to combat resistant infections and parasitic diseases.
Used in Material Science:
4-(HYDROXYMETHYL)PYRIDINE-2-CARBOXAMIDE's versatile reactivity and ability to form coordination complexes also make it a candidate for applications in material science, where it can be used to develop new materials with unique properties for various applications, such as sensors, catalysts, or advanced materials for energy storage and conversion.

Upstream product

• 1452-77-3 pyridine-2-carboxylic acid amide 
• 67-56-1 methanol 
• 166766-77-4 4-ethoxycarbonyl-2-pyridinecarboxamide 
• 923169-37-3 4-(hydroxymethyl)pyridine-2-carboxylic acid 
• 117423-43-5 2-cyano-4-[{(tert-butyldimethylsilyl)oxy}methyl]pyridine 
• 586-95-8 pyridine-4-methanol 
• 117423-41-3 4-((tert-butyldimethylsilyloxy)methyl)pyridine 
• 77287-34-4 formamide 
• 71935-32-5 2-Cyano-4-(hydroxymethyl)pyridine 

Downstream Products

• 105250-17-7 2-amino-4-hydroxymethylpyridine 

Relevant articles and documents

Photochemical Alkylation, Hydroxyalkylation, and Alkoxylation of Pyridinecarboxamides in Alcohol

The UV-irradiation of 2- and 4-pyridinecarboxamides in alcohol brings about alkylation and/or hydroxyalkylation in the pyridine ring.In the irradiation of 3-pyridinecarboxamide in the presence of sulfuric acid, ionic reaction (alkoxylation at the 2- and 6-position) and radical reaction (alkylation at the 4- and 6-position) occur in parallel.The effects of quenchers indicate that two alkylation products originate from one excited triplet state which is quenched by energy-transfer mechanism and that two alkoxylation products originate from the excited singlet state.

MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Method for synthesizing 2-aminopyridine-4-methanol

The invention discloses a method for synthesizing 2-aminopyridine-4-methanol. The method comprises the following steps that 4-pyridylcarbinol reacts with an aqueous formamide solution to prepare a second compound; the second compound and a NaOH solution are mixed and placed into a reaction still, the temperature is controlled within 5-10 DEG C, a NaBrO solution is added dropwise into the reactionstill, after the dropwise addition is completed, the reaction is continuously conducted for 1-2 hours at the temperature, then the temperature is raised to 50-60 DEG C to enable the reaction to be conducted continuously for 1 hour and then reduced to room temperature, ethyl acetate is used for carrying out extraction several times, organic phases are combined, distillation under reduced pressure is conducted to remove ethyl acetate, and 2-aminopyridine-4-methanol is prepared. The synthesis method has the advantages that the operation is simple, the conditions are mild, few byproducts are generated, and the product purity and yield are high.

1,3-THIAZOLE-5-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS

This invention relates to novel 1, 3- thiazole-5 -carboxamide compounds of formula (I), pharmaceutical compositions containing such compounds, and the use of those compounds or compositions as cancer chemotherapeutic agents.

2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS

A compound having the formula (1) in which the ring containing E is a phenyl, a pyridine, or a pyrimidine. In formula (1) the symbol A represents (see structures) wherein the group R4 represents halogen, CF3, or H, provided that the maximum number of CF3 groups on any A is 2, and the maximum number of hydrogens on A is 2 for the A groups which together with the carbon atoms to which they are attached form 6-membered rings, and the maximum number of hydrogens on A is 1 for the A group which together with the carbon atoms to which it is attached forms a 5-membered ring. Z represents N or CH when E forms a phenyl ring, and represents CH when E forms a pyridine or pyrimidine. The groups R1, R2 and R3 and the subscripts a, b, and d are as defined in the text and claims. Pharmaceutical compositions containing a compound of formula (1) and methods of treating cancer using compounds of formula (1) are also disclosed and claimed.

2-AMINOTHIOPHENECARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS

This invention relates to novel 2-aminothiophenecarboxamide compounds, pharmaceutical compositions containing such compounds, and the use of those compounds or compositions as cancer chemotherapeutic agents.

1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS

This invention relates to novel 1 -Methyl- lH-pyrazole-4-carboxamide compounds, pharmaceutical compositions containing such compounds, and the use of those compounds or compositions as cancer chemotherapeutic agents.

NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT

A subject of the present invention is to provide a novel aromatic five- or six-memberd heterocyclic derivative having 4-pyridylalkylthio as a substituent or a salt thereof which is useful as a pharmaceutical. Compound represented by the following general formula [I] or salts thereof are useful as therapeutic agents for diseases in which angiogenesis or augmentation of vascular permeability is involved. In the formula, ring "A" is a benzene ring or an aromatic five- or six-memberd heterocycle which can be fused with a cycloalkane ring, "B" is alkylene, R1 and R2, the same or different, are H, OH, substituted or unsubstituted alkoxy and the like, X and Y, the same or different, are group(s) selected from H, halogen, OH, substituted or unsubstituted alkoxy and the like respectively, p is 0, 1 or 2, and q is 0 or 1.

An alternative synthesis of the NMDA antagonist CGS 19755 via free radical carbamoylation of ethyl isonicotinate.

The NMDA antagonist CGS 19755 (cis-4-phosphonomethyl-2-piperidinecarboxylic acid) has been prepared by applying Minisci reaction conditions [formamide, hydrogen peroxide, iron(II) sulfate] to ethyl isonicotinate, reduction of the ester with sodium borohydride, alcoholysis of the 2-carboxamide, formation of 4-(diethylphosphonomethyl)-2-pyridinecarboxylate, hydrogenation of the pyridine nucleus, and acid hydrolysis. The overall, unoptimized yield was around 11%. The procedure employs cheap starting materials, is practical and avoids the use of toxic and hazardous cyanotrimethylsilane which is used in the published procedure.